Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients
Non-interventional Study on Uncontrolled Hypertensive Patients for Evaluating Efficacy of Candesartan Cilexetil as Monotherapy or add-on Therapy.
1 other identifier
observational
1,940
1 country
16
Brief Summary
The purpose of this study is to observe treatment with candesartan cilexetil 16mg for 8 weeks, in uncontrolled hypertensive patients, in improvement of achieving of treatment goals and impact on blood pressure level in patients with uncontrolled hypertension treated with candesartan cilexetil.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2007
Shorter than P25 for all trials
16 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2007
CompletedFirst Submitted
Initial submission to the registry
December 13, 2007
CompletedFirst Posted
Study publicly available on registry
December 14, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2008
CompletedAugust 19, 2010
August 1, 2010
5 months
December 13, 2007
August 18, 2010
Conditions
Keywords
Interventions
Eligibility Criteria
hypertensive patients not at BP target (according to ESC Guideline for the management of hypertension, 2003), already treated with candesartan cilexetil 16 mg/day
You may qualify if:
- diagnosis of essential hypertension (mild or moderate as defined in European Guidelines of Hypertension, 2003), that are treated already with candesartan cilexetil 16mg o.d. within last 2 weeks or more, according to Romanian approved Atacand SPC. Written informed consent to allow access and use(analysis) of data collected
You may not qualify if:
- Patients not to be included in the programme: patients who have any contraindication to the product as detailed in Romanian approved Atacand SPC. Use of specific concomitant medication known to present a potential safety concern according to Romanian approved SPC
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (16)
Research Site
Bacau, Romania
Research Site
Brasov, Romania
Research Site
Brăila, Romania
Research Site
Bucharest, Romania
Research Site
Cluj-Napoca, Romania
Research Site
Constanța, Romania
Research Site
Craiova, Romania
Research Site
Galati, Romania
Research Site
Ghiroda, Romania
Research Site
Iași, Romania
Research Site
Lugoj, Romania
Research Site
Oradea, Romania
Research Site
Piteşti, Romania
Research Site
Ploieşti, Romania
Research Site
Sibiu, Romania
Research Site
Timișoara, Romania
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Mihai Isvoranu
AstraZeneca
- STUDY DIRECTOR
Gabriela Teodorescu
AstraZeneca
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
December 13, 2007
First Posted
December 14, 2007
Study Start
September 1, 2007
Primary Completion
February 1, 2008
Study Completion
February 1, 2008
Last Updated
August 19, 2010
Record last verified: 2010-08